Vimarsana
Biggest News Aggregation in the World

Prospective Multicenter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prospective Multicenter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prospective Multicenter Today - Breaking & Trending Today

Study reports 'excellent' outcomes for patients receiving optimized treatment for atrial fibrillation - Vimarsana News

Study reports 'excellent' outcomes for patients receiving optimized treatment for atrial fibrillation

Atrial fibrillation (AF) is the most common form of arrythmia or irregular heartbeat worldwide, impacting millions of people in the U.S. alone. In a study published in Heart Rhythm, researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, analyzed real-world clinical data to measure the impact of evidence-based best-practices on patient outcomes for the most common AF procedure: radiofrequency (RF)-based ablation.

GSK's RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review - Vimarsana News

GSK's RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results.

GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk -February 06, 2024 at 07:04 am EST - Vimarsana News

GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk -February 06, 2024 at 07:04 am EST

Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population Adults aged 50 and above with underlying medical...

New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months - Vimarsana News

New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months

/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published...

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC - Vimarsana News

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy...